All In MedTech

Device Trial Radar · NCT05867407

A Multicenter Pragmatic Implementation Study of ECG-AI-Based Clinical Decision Support Software to Identify Low LVEF

A Prospective Pragmatic Cluster-Randomized Care-as-Usual Controlled Study to Evaluate the Impact of an ECG-Based AI Algorithm to Detect Low Left Ventricular Ejection Fraction on Diagnosis Rates of LVEF ≤40% in the Outpatient Setting

Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 11,610 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

11,610

Actual

Start

Jun 13, 2024

Primary completion

May 30, 2025

Study completion May 30, 2025

Sponsor

Lead sponsor
Anumana, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Mayo Clinic
First posted
May 22, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Screening
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, cluster-randomized, care-as-usual controlled trial to evaluate the impact of an ECG-based artificial intelligence (ECG-AI) algorithm to detect low left ventricular ejection fraction (LVEF) on diagnosis rates of LVEF ≤ 40% in the outpatient setting. The objective of this study is to evaluate the impacts of an ECG-AI algorithm to detect low LVEF and an associated Medical Device Data System when used during routine outpatient care. The study will be conducted in 2 phases: feasibility assessment phase and clinical impact phase.

Conditions

  • Ventricular Ejection Fraction

Interventions

  • Anumana Low EF AI-ECG AlgorithmDevice

    Clinician will have access to the Anumana Low EF AI-ECG algorithm via a link in the patient's electronic health record which will display results applied to patients' ECGs, as well as supporting information. Using the results of the algorithm, combined with the clinician's knowledge of patient-specific risk factors, the clinician will determine whether further evaluation is warranted.

  • Care-as-UsualOther

    Clinicians will not have access to the Anumana Low EF AI-ECG algorithm and will provide care-as-usual.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Diagnosis rates of low ejection fraction of less than or equal to 40 percent by echocardiography compared to care-as-usualTime frame: 90 days

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • Mayo Clinic Florida

    Jacksonville, Florida

  • Mayo Clinic Rochester

    Rochester, Minnesota

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.